LDS/Medical Tests/Human Platelet Antigen 1 (HPA-1) Genotyping

Human Platelet Antigen 1 (HPA-1) Genotyping

Human platelet antigen (HPA) genotyping can provide information in the diagnosis and prevention of disorders such as Fetal and neonatal alloimmune thrombocytopenic purpura (FNAIT or NAIT), post-transfusion thrombocytopenic purpura (PTTP), and refractoriness to platelet transfusion therapy. It is rarely used in the investigation of unexplained intracranial hemorrhage or thrombocytopenia in the fetal or neonatal periods.

HPA genetic profiling includes six different genes, namely - ITGB3, GP1BA, ITGA2B, ITGA2, and CD109. ITGB3 gene, also known as GPIIIa (GP3A) encodes beta3 subunit of a receptor protein called integrin alphaIIb/beta3 (αIIbβ3, also known as HPA-1 antigen), that is found on the surface of platelets. More than 98% of Caucasian individuals have “a” type allele of HPA-1 and designated as HPA-1a while the remaining 2% have “b” type of allele variant (HPA-1b). It is believed that single nucleotide transition from T to C at a nucleotide of the ITGB3 gene cause substitution of amino acid leucine to proline at GP3A, resulting in the conversion of HPA-1a into HPA-1b. Women with HPA-1b allele variants are at risk for alloimmunization during pregnancy if her partner is homozygous HPA-1a or heterozygous HPA11a/b and contributes the HPA-1a allele to the fetus.

The allogenic mismatch between HPA-1a fetus and HPA-1b-homozygous mother leads to maternal immunization with the production of anti-HPA-1a IgG antibodies. This maternal-fetal HPA incompatibility and alloantigens on platelets transferred across the placenta cause the destruction of fetal platelets resulting in thrombocytopenia (FNAIT). The incidence of FNAIT is 1 in 5000 births and is characterized by severe thrombocytopenia, intracranial hemorrhage, widespread purpura, and gastrointestinal hemorrhage. About 5-10% of the affected fetus, the intracranial hemorrhage may result in fatality and survivors may have intellectual disability, seizures, cerebral palsy and cortical blindness. The recurrence risk and severity increase with subsequent pregnancies. Therefore, screening for HPA-1 phenotype either by antigen testing or genotyping is recommended in women at risk. All pregnancies after the history of first FNAIT should be screened.

Similarly, post-transfusion purpura (PTP) may occur in transfusion recipients who are HPA-1b allele variants and who have developed antibodies against HPA-1 antigen from prior transfusion or pregnancy. The incidence of PTP is about 1 in 50,000-100,000 transfusions.

  • Useful in detecting HPA-1b genotype in women who have developed post-transfusion purpura or fetal platelets resulting in thrombocytopenia
  • Useful to evaluate thrombocytopenia and unexplained neonatal intracranial hemorrhage
  • Useful to assess the risk of fetal platelets resulting in thrombocytopenia in future pregnancies
  • The genotyping will identify following conditions:
  • HPA-a/a homozygous: 2 copies of common “a” allele
  • HPA-b/b homozygous: 2 copies of less common “b” allele, high risk for alloimmunization during pregnancy
  • HPA-a/b heterozygous: 1 copy of common “a” allele+ 1 copy of less common “b” allele, low risk for alloimmunization during pregnancy

HPA-a/a homozygous: 2 copies of common “a” allele

HPA-b/b homozygous: 2 copies of less common “b” allele

Allele Specific Primer Extension by Polymerase chain reaction (PCR) followed by fluorescent monitoring (ARMS). Genotyping by Next Generation Sequencing (NGS).

Whole blood (Parental Genotyping), Amniotic fluid, cultured amniocytes, maternal cell contamination specimen.

Stability

Whole blood

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable

Amniotic fluid

  • Ambient: 48 hours
  • Refrigerated: unacceptable
  • Frozen: unacceptable
CBC with platelet count, Maternal platelet count, Antiplatelet antibody, Platelet antigen genotyping panel.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login